Exhibit 10.1
AMENDMENT TO NOTICE OF AWARD –
RFA 10-05A - CIRM Disease Team
Therapy Development Awards - Part II Research Award
California Institute for Regenerative Medicine
Amendment Number: 03
Amendment Date: 12/11/17
| Award Number: | DR2A-05735 | Total Award Amount: | $14,405,857 |
| Awardee Name: | Capricor, Inc |
Project Period Start Date: Project Period End Date: |
01/01/2013 11/30//2017 |
Principal Investigator or Program Director:
|
Rachel Ruckdeschel Smith
|
||
| Project Title: | Allogeneic Cardiac-Derived Stem Cells for Patients Following a Myocardial Infarction | ||
| Authorized Organization Official and Address: | Official and Address to Receive Payments: |
|
AJ Bergmann VP of Finance 8840 Wilshire Blvd. 2nd Floor Beverly Hills, CA 90211 |
AJ Bergmann VP of Finance 8840 Wilshire Blvd., 2nd Floor Beverly Hills, CA 90211 |
This award is closed, effective 11/30/2017, based on the completion of the final Operational Milestone (Operational Milestone #6 “File final Clinical Study Report”). CIRM recognizes that Capricor, Inc. has abandoned the CIRM-Funded Project as noted in the Notice of Abandonment letter from Capricor, Inc. to CIRM dated 11/17/2017. As such, pursuant to Section 4.10 of the Loan Agreement between CIRM and Capricor, Inc. and Article VII, Section I of the CIRM Loan Administration Policy, Capricor, Inc.’s Loan Balance is forgiven, subject to reinstatement pursuant to those provisions. No expenses may be incurred after 11/30/2017, and any unexpended funds shall be returned to CIRM. A Final Operational Milestone Financial Report is due by 02/01/2018.
/s/ Maria T. Millan, M.D.
Maria T. Millan, M.D.
President and CEO, CIRM
/s/ Rachel Ruckdeschel Smith
Rachel Ruckdeschel Smith
Principal Investigator, Capricor, Inc
/s/ AJ Bergmann
Awardee Authorized Signatory, Capricor, Inc